Rapamycin Exacerbates Staphylococcus aureus Pneumonia by Inhibiting mTOR-RPS6 in Macrophages

Fang-Yi Yu1, Kua Zheng1, Yin-Fang Wu1

  • 1Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.

PubMed
Abstract

Insights

Rapamycin (Rapa) worsens Staphylococcus aureus (S. aureus) pneumonia by increasing inflammation in macrophages. Inhibiting the mTOR-RPS6 pathway boosts inflammatory responses, worsening S. aureus pneumonia outcomes.

Area of Science:

  • Immunology
  • Microbiology
  • Pharmacology

Background:

  • Staphylococcus aureus (S. aureus) is a common cause of bacterial pneumonia.
  • Rapamycin (Rapa) is an immunosuppressant drug with potential immunomodulatory effects.
  • The role of Rapa in S. aureus pneumonia requires further elucidation.

Purpose of the Study:

  • To investigate the effect of Rapamycin (Rapa) on Staphylococcus aureus (S. aureus) pneumonia.
  • To clarify the underlying mechanisms of Rapa's action in S. aureus pneumonia.

Main Methods:

  • S. aureus pneumonia mouse models and in vitro macrophage cultures were used.
  • Investigated mTOR-RPS6 pathway phosphorylation and phagocytosis.
  • Utilized myeloid cell-specific Mtor knockout mice for in vivo validation.

Main Results:

  • Rapa exacerbated S. aureus pneumonia, increasing chemokine secretion and inflammatory cell infiltration.
  • In vitro, Rapa upregulated macrophage chemokine and cytokine secretion.
  • mTOR-RPS6 pathway inhibition increased inflammation; Rapa did not enhance phagocytosis.

Conclusions:

  • Rapamycin exacerbates S. aureus pneumonia by amplifying macrophage inflammatory responses.
  • Inhibition of the mTOR-RPS6 pathway promotes inflammation, worsening S. aureus pneumonia severity and tissue damage.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
1.4K